<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926183</url>
  </required_header>
  <id_info>
    <org_study_id>1881</org_study_id>
    <nct_id>NCT02926183</nct_id>
  </id_info>
  <brief_title>Study of NAC of GA Therapy for Patients With BRPC</brief_title>
  <official_title>Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international
      oncology meeting and represents a new standard regimen in the treatment of metastatic
      pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy
      on survival time as a preoperative chemotherapy, the investigators use the NAC-GA regimen
      includes only two cycles (three times weekly and one week rest) of GA regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international
      oncology meeting and represents a new standard regimen in the treatment of metastatic
      pancreatic cancer. GA is one of the high response rate treatment regimen, the investigators
      considered as a promising treatment as neoadjuvant chemotherapy. On the other hand,
      incidences of grade 3 or 4 neutropenia, febrile neutropenia and peripheral neuropathy were
      significantly higher in the g group compared with gemcitabine group. Therefore, it was
      decided to consider the balance of safety and efficacy on survival time as a preoperative
      chemotherapy, the investigators use the NAC-GA regimen includes only two cycles (three times
      weekly and one week rest) of GEMABR regimen. The investigators also evaluate Recurrence free
      survival from the first day of protocol therapy, safety of the protocol therapy(Adverse
      effect), morbidity based on Clavien Dindo classification of more than Grade 3, response rate,
      preoperative/postoperative tumor marker (CA19-9, CEA), rate of mornalization, reduction rate
      of SUVmax value on PET-CT (limited only for PET-CT available institutions), chemotherapeutic
      effect grade based on Evans classification, resection rate, R0 resection rate, surgical data
      (operative time, blood loss, transfusion, postoperative hospital day), the overall morbidity
      rates (Reoperation, rate of re-admission, mortality), number of patient rate in postoperative
      adjuvant therapy (entry rate, completion rate), dose intensity for borderline resectable
      pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival time from the first day of protocol therapy</measure>
    <time_frame>Up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival from the first day of protocol therapy</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity based on Clavien Dindo classification of more than Grade3</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapeutic effect grade based on Evans classification</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall morbidity rates based on Clavien Dindo classification</measure>
    <time_frame>Up to 50 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient rate in postoperative adjuvant therapy</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine plus nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel</intervention_name>
    <description>Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.</description>
    <arm_group_label>Gemcitabine plus nab-paclitaxel</arm_group_label>
    <other_name>NAC-GA for BRPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically diagnosed as pancreatic adenocarcinoma, and consistent
             with NCCN guideline (Version 2. 2016) borderline resectable-arterial, borderline
             resectable-venous

          2. Case with measurable lesion

          3. First line treatment

          4. PS (ECOG) 0-1

          5. &gt;= 20 years old and &lt;80 years old

          6. The following criteria must be satisfied in laboratory tests within 14 days of
             registration

               -  WBC count&lt;=12,000/mm3

               -  Neutrophil count&gt;=1,500/mm3

               -  Hb &gt;= 9.0g/dl

               -  Plt &gt;= 100,000/mm3

               -  T.Bil &lt;2.0mg/dl (&lt;3=.0mg/dl in biliary drainage case)

               -  Serum Cr&lt;=upper limits of normal (ULN)

               -  AST, ALT &lt;= 2.5xULN

          7. Written informed consent to participate in this study

        Exclusion Criteria:

          1. Severe drug hypersensitivity

          2. Multiple primary cancers within 5 years

          3. Severe infection

          4. With grade2 or more severe peripheral neuropathy

          5. Interstitial pneumonia or pulmonary fibrosis

          6. With uncontrollable pleural effusion or ascites

          7. With uncontrollable diabetes mellitus

          8. With uncontrollable heart failure, angina, hypertension, arrhythmia

          9. With severe neurological/psychological symptoms

         10. With watery diarrhea

         11. Pregnant or lactating women or women with unknown or suspected pregnancy

         12. Inappropriate patients for entry on this study in the judgement of the investigator

         13. Diagnosed as Resectable/Unresectable pancreatic carcinoma on NCCN guideline (Version
             2.2016)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ken-ichi Okada, M.D., Ph.D.</last_name>
    <phone>+81-73-441-0613</phone>
    <email>okada@wakayama-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hirosaki University</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keinosuke Ishido, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hirochika Toyama, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiro Fujimoto, M.D., PhD.</last_name>
    </contact>
    <investigator>
      <last_name>Kazuhiro Suzumura, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nara Medical University</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masayuki Sho, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sohei Satoi, M.D., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinki University</name>
      <address>
        <city>Sayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ippei Matsumoto, M.D., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hidetoshi Eguchi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical University</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitsuhiro Asakuma, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiga Medical University</name>
      <address>
        <city>Ohtsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaji Tani, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hideyuki Yoshitomi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gifu University</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kazuhiro Yoshida, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshiaki Murakami, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University</name>
      <address>
        <city>Kumamoto city</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daisuke Hashimoto, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hisashi Ikoma, M.D., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto University</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toshihiko Masui, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsutomu Fujii, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryosuke Amano, M.D., PhD.</last_name>
    </contact>
    <investigator>
      <last_name>Ryosuke Amano, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1 Kimiidera</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken-ichi Okada, M.D., Ph.D.</last_name>
      <phone>+81-73-441-0613</phone>
      <email>okada@wakayama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hiroki Yamaue, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wakayama Medical University</investigator_affiliation>
    <investigator_full_name>Hiroki Yamaue</investigator_full_name>
    <investigator_title>NAC-GA investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

